LONDON HORMONE CLINIC LIMITED

Company Registration Number:
10244199 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2025

Period of accounts

Start date: 01 January 2025

End date: 31 December 2025

LONDON HORMONE CLINIC LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2025

Balance sheet
Notes

LONDON HORMONE CLINIC LIMITED

Balance sheet

As at 31 December 2025


Notes

2025

2024


£

£
Fixed assets
Tangible assets: 3 101,644 141,476
Total fixed assets: 101,644 141,476
Current assets
Debtors:   105,651 121,348
Cash at bank and in hand: 112,619 129,271
Total current assets: 218,270 250,619
Creditors: amounts falling due within one year: 4 (164,479) (289,180)
Net current assets (liabilities): 53,791 (38,561)
Total assets less current liabilities: 155,435 102,915
Provision for liabilities: (13,102) (8,372)
Total net assets (liabilities): 142,333 94,543
Capital and reserves
Called up share capital: 1,000 1,000
Profit and loss account: 141,333 93,543
Shareholders funds: 142,333 94,543

The notes form part of these financial statements

LONDON HORMONE CLINIC LIMITED

Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 27 June 2026
and signed on behalf of the board by:

Name: Janine Toledano
Status: Director

The notes form part of these financial statements

LONDON HORMONE CLINIC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Tangible fixed assets and depreciation policy

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: Property improvements - over 5 years Plant and machinery - over 4 years

Other accounting policies

Debtors Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Creditors Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. Taxation A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted. Provisions Provisions (i.e. liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably. Operating Leases Rentals paid under operating leases are recognised as an expense on a straight line basis over the lease term. Pensions Contributions to defined contribution plans are expensed in the period to which they relate.

LONDON HORMONE CLINIC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

2. Employees

2025 2024
Average number of employees during the period 10 10

LONDON HORMONE CLINIC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

3. Tangible Assets

Total
Cost £
At 01 January 2025 219,672
Additions 995
At 31 December 2025 220,667
Depreciation
At 01 January 2025 78,196
Charge for year 40,827
At 31 December 2025 119,023
Net book value
At 31 December 2025 101,644
At 31 December 2024 141,476

LONDON HORMONE CLINIC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

4. Creditors: amounts falling due within one year note

Creditors: amounts falling due within one year 2025 Trade creditors £31,714 Taxation and social security costs £30,816 Other creditors £101,949 Total £164,479 2024 Trade creditors £3,494 Taxation and social security costs £136 Other creditors £285,550 Total £289,180

LONDON HORMONE CLINIC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

5. Financial commitments

Other Financial Commitments Total future minimum payments under non-cancellable operating leases £225,000 (2024 - £315,000)

LONDON HORMONE CLINIC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2025

6. Loans to directors

Name of director receiving advance or credit: Jan Toledano
Description of the loan: At the year end the amount due to the director was £59,971 (2024 - £60,670). The balance is unsecured, interest free and repayable on demand.
£
Balance at 01 January 2025 60,670
Advances or credits repaid: 699
Balance at 31 December 2025 59,971